Sugi Predict

Sugi Predict / Compounds / SCHEMBL558972

SCHEMBL558972

SCHEMBL558972

COc1cccc(CC(=O)C=[N+]=[N-])c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CTBP2 P56545 1/20 0.52
▸ CYP1A2 P05177 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MMP13 P45452 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ SIGMAR1 Q99720 1/20 0.45
▸ MTNR1A P48039 1/20 0.45
▸ MTNR1B P49286 1/20 0.45
▸ USP2 O75604 1/20 0.45
▸ CMA1 P23946 1/20 0.44
▸ IDO1 P14902 1/20 0.44
▸ AGXT P21549 1/20 0.44
▸ TAAR1 Q96RJ0 1/20 0.44
▸ RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL559841 0.81 HTT (0.53) CTBP2POLBALDH1A1HTTSMN1; SMN2
SCHEMBL18827733 0.80 CTBP2 (0.56) CTBP2CYP1A2POLBALDH1A1HTT
SCHEMBL1024193 0.79 CTBP2 (0.55) CTBP2CYP1A2POLBALDH1A1HTT
SCHEMBL28026090 0.78 CTBP2 (0.60) CTBP2CYP1A2POLBALDH1A1HTT
SCHEMBL16836020 0.78 LMNA (0.51) CYP1A2POLBALDH1A1HTTSMN1; SMN2
SCHEMBL5613277 0.78 CTBP2 (0.54) CTBP2CYP1A2POLBALDH1A1HTT
SCHEMBL4071390 0.77 CTBP2 (0.64) CTBP2CYP1A2POLBALDH1A1HTT
SCHEMBL7888669 0.77 MTNR1A (0.55) POLBALDH1A1HTTSMN1; SMN2MTNR1A
SCHEMBL5505402 0.77 CTBP2 (0.52) CTBP2CYP1A2POLBALDH1A1HTT
SCHEMBL19649636 0.77 CTBP2 (0.56) CTBP2CYP1A2POLBALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066378-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2025-02-27 — — US disclosed
US-12162887-B2 Spiro-oxazolones HOFFMANN-LA ROCHE INC. (US) 2024-12-10 — — US disclosed
US-20230106150-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2023-04-06 — — US disclosed
US-11578077-B2 Spiro-oxazolones HOFFMANN-LA ROCHE INC. (US) 2023-02-14 — — US disclosed
US-20200039997-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2020-02-06 — — US disclosed
US-10479796-B2 Spiro-oxazolones HOFFMAN-LA ROCHE INC. (US) 2019-11-19 — — US disclosed
EP-3083633-B1 SPIRO-OXAZOLONES HOFFMANN LA ROCHE (CH) 2017-11-29 — — EP disclosed
US-9645128-B2 Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity JNC CORPORATION (JP) 2017-05-09 — — US disclosed
US-9645128-B2 Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity JNC CORPORATION (JP) 2017-05-09 — — US disclosed
US-20170008901-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2017-01-12 — — US disclosed
US-8765921-B2 Coelenterazine analogs and manufacturing method thereof JNC CORPORATION (JP) 2014-07-01 — — US disclosed
US-20140024058-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2014-01-23 — — US disclosed
US-20140024058-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2014-01-23 — — US disclosed
US-8546568-B2 Coelenterazine analogs and manufacturing method thereof JNC CORPORATION (JP) 2013-10-01 — — US disclosed
US-8546568-B2 Coelenterazine analogs and manufacturing method thereof JNC CORPORATION (JP) 2013-10-01 — — US disclosed
US-20120035070-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2012-02-09 — — US disclosed
US-20120035070-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2012-02-09 — — US disclosed
US-20090306052-A1 INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS GLAXO GROUP LIMITED 2009-12-10 — — US disclosed
EP-1833796-A1 INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS GLAXO GROUP LIMITED (GB) 2007-09-19 — — EP disclosed
WO-2006061193-A1 INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS GLAXO GROUP LIMITED (GB) 2006-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306052-A1 INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS NLN, INMT, INA CTBP2 2181/4885CYP1A2 185/4885POLB 3728/4885
US-12162887-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 CTBP2 3558/4885CYP1A2 1341/4885POLB 2449/4885
US-11578077-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 CTBP2 3558/4885CYP1A2 1341/4885POLB 2449/4885
US-20250066378-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 CTBP2 3558/4885CYP1A2 1341/4885POLB 2449/4885
US-20200039997-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 CTBP2 3558/4885CYP1A2 1341/4885POLB 2449/4885
US-20170008901-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 CTBP2 3558/4885CYP1A2 1341/4885POLB 2449/4885
US-20120035070-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF GLB1, CEL, SI CTBP2 1615/4885CYP1A2 149/4885POLB 4189/4885
US-20230106150-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 CTBP2 3558/4885CYP1A2 1341/4885POLB 2449/4885
US-10479796-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 CTBP2 3558/4885CYP1A2 1341/4885POLB 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.